Good afternoon :)
Switch to
Place Order

Glenmark Pharmaceuticals Ltd

GLENMARK
Health CarePharmaceuticals
SmallcapWith a market cap of ₹14,056 cr, stock is ranked 291
Moderate RiskStock is 2.11x as volatile as Nifty
497.350.80 (-0.16%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹14,056 cr, stock is ranked 291
Moderate RiskStock is 2.11x as volatile as Nifty

Key Metrics

PE RatioPE Ratio
14.49
PB RatioPB Ratio
1.99
Dividend YieldDiv. Yield
5.02%
Sector PESector PE
38.40
Sector PBSector PB
5.11
Sector Div YldSctr Div Yld
0.67%

Forecast & RatingsDetailed Forecast 

55%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Glenmark Pharmaceuticals Limited is a global pharmaceutical company engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs).

Brands

Glenmark Pharma

Pharmaceutical company

Brands

Glenmark Pharma

Pharmaceutical company

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Financial TrendFinancial statements 

20182019202020219.1710.2410.8311.040.800.920.780.97
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Press Release 
Announced OnJan 17, 2022

Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 17, 2022, titled "Glenmark Pharmaceuticals receives ANDA tentative approval for Regadenoson Injection, 0.4 mg/5 mL (0.08 mg/mL) Single‐Dose Pre‐Filled Syringe". | Download

Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 17, 2022, titled "Glenmark Pharmaceuticals receives ANDA tentative approval for Regadenoson Injection, 0.4 mg/5 mL (0.08 mg/mL) Single‐Dose Pre‐Filled Syringe". | Download

Press Release 
Announced OnJan 14, 2022

Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 14, 2022, titled "Glenmark Specialty S.A. (Switzerland) receives NDA Approval by the United States Food and Drug Administration (FDA) for Ryaltris Nasal Spray for the Treatment of Symptoms of Seasonal Allergic Rhinitis in Adults and Pediatric Patients 12 Years of Age and Older". | Download

Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 14, 2022, titled "Glenmark Specialty S.A. (Switzerland) receives NDA Approval by the United States Food and Drug Administration (FDA) for Ryaltris Nasal Spray for the Treatment of Symptoms of Seasonal Allergic Rhinitis in Adults and Pediatric Patients 12 Years of Age and Older". | Download

Cash Dividend 
Ex. DateSep 8, 2021

Final • Div/Share: ₹ 2.5

See all events